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1. Introduction 
Heart disease is one of the leading causes of mortality worldwide. Because adult 
cardiomyocytes (CMs) lack the ability to regenerate, malfunctions or significant loss of CMs 
due to disease or aging can lead to cardiac arrhythmias, heart failure, and subsequently 
death. Heart transplantation for patients with end stage heat failure is limited by the 
number of donor organs available. Cell-based therapies offer a promising alternative for 
myocardial repair, but there are significant challenges involved. The transplantation of 
human CMs, eg fetal CMs, is difficult for practical and ethical reasons, thus cells of non-
cardiac lineage, such as skeletal myoblasts (Murry et al., 1996; Menasche et al., 2003) and 
mesenchymal stem cells (Shake et al., 2002; Toma et al., 2002), have been considered as 
alternatives. Animal studies and clinical trials involving these cells have yielded conflicting 
results. Transplanted non-cardiac cells such as bone marrow-derived hematopoietic cells do 
not transdifferentiate into the cardiac lineage (Balsam et al., 2004; Murry et al., 2004). They 
also do not integrate into the host myocardium. For instance, the lack of electrical 
integration of skeletal myoblasts after their autologous transplantation into the myocardium 
resulted in the generation of malignant ventricular arrhythmias, which led to the premature 
termination of clinical trials involving skeletal myoblasts (Menasche et al., 2003; Smits et al., 
2003). Therefore, an alternative cell source is needed. 
2. Human embryonic stem cells and induced pluripotent stem cells 
Human embryonic stem cells (hESCs), isolated from the inner cell mass of blastocysts, can 
self-renew while maintaining their pluripotency to differentiate into all cell types (Thomson 
et al., 1998), including CMs (Kehat et al., 2001; Mummery, C. et al., 2002; Xu, C. et al., 2002; 
Xue et al., 2004; Mummery, C. et al., 2003). Therefore, hESCs may provide an unlimited ex 
vivo source of CMs for cell-based heart therapies. The laboratories of Yamanaka (Takahashi 
et al., 2007) and Thomson (Yu et al., 2007) showed that adult somatic cells can be 
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reprogrammed to become pluripotent hES-like cells (a.k.a. induced pluripotent stem cells or 
iPSCs) via the forced expression of four pluripotency genes (Oct4, Sox2, c-Myc, and Klf4 or 
Oct4, Sox2, Nanog, and Lin28) (Takahashi and Yamanaka, 2006; Takahashi et al., 2007; 
Aasen et al., 2008). More recent studies have further demonstrated the successful use of less 
pluripotency factors (Huangfu et al., 2008; Kim, J. B. et al., 2008; Nakagawa et al., 2008) and 
non-viral methods (e.g., with synthetic modified RNA (Warren et al., 2010)) to reprogram 
somatic cells into iPSCs. Although concerns such as induced somatic coding mutations 
(Gore et al., 2011) have yet to be fully addressed, hiPSCs have morphology, gene expression 
profile, epigenetic status, in vitro and in vivo differentiation capacities similar to hESCs 
(Takahashi et al., 2007; Yu et al., 2007).  
3. Differentiation of hESC into CMs 
Previous studies studies have demonstrated that hESCs and hiPSCs can spontaneously 
differentiate into CMs when they aggregate in suspension to form embryoid bodies (Xu, C. 
et al., 2002; Zwi et al., 2009). Recent studies have focused on improving the yield and purity 
of CM differentiation. For instance, hESC differentiation into the CM lineage can be 
enhanced by coculture with visceral endoderm-like cells (Mummery, C. et al., 2003; 
Mummery, C. L. et al., 2007). Recently, an effective protocol for cardiac differentiation has 
been successfully developed by the Keller laboratory involving the stage-specific addition of 
growth factors, including BMP4, Activin-A, DKK, bFGF etc, to drive sequential 
differentiation into the epiblast, mesoderm and CMs, resulting in greatly increased yield of 
up to 50%, as gauged by the proportion of cells that express cardiac troponin T (Yang et al., 
2008). Other approaches have also been pursued, utilizing different extracellular matrices, 
serum (Passier et al., 2005) and insulin elimination (Xu, X. Q. et al., 2008). Besides improving 
the yield of CM differentiation, the isolation of a pure population of CMs is also important 
in order to prevent malignancy and arrhythmias. Various purification methods have been 
developed including Percoll gradient centrifugation (Xu, C. et al., 2002), optical signatures 
(Chan, J. W. et al., 2009) and genetic selection based on the expression of a reporter protein 
under the transcriptional control of a cardiac-restricted promoter (e.g., -myosin heavy 
chain (-MHC) (Anderson et al., 2007), ventricular myosin light chain (MLC-2v) (Huber et 
al., 2007; Fu et al., 2010)). 
4. Properties of hESC-derived CMs (hESC-CMs) 
4.1 Human ESC-CMs have molecular and structural properties of CMs 
Gene expression profiles have been examined for hESC-CMs cultured in different 
laboratories using different differentiation protocols and from different hESC lines (Kehat et 
al., 2001; Xu, C. et al., 2002; Snir et al., 2003; Norstrom et al., 2006). There is now consensus 
that hESC-CMs express transcription factors and structural proteins specific to human 
cardiomyocytes (Kehat et al., 2001; Xu, C. et al., 2002; Snir et al., 2003; Norstrom et al., 2006). 
Human ESC-CMs express cardiac-specific transcription factors such as NKx2.5, GATA4 and 
Mef-2 (Kehat et al., 2001; Xu, C. et al., 2002), which are expressed in the precardiac 
mesoderm but persist in the heart during development. Structural components of the 
myofibers can also be detected in hESC-CMs. These include , - and sarcomeric-myosin 
heavy chain (MHC), atrial and ventricular forms of myosin light chain (MLC-2a and –2v), 
tropomyosin, -actinin and desmin (Kehat et al., 2001; Xu, C. et al., 2002; Norstrom et al., 
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2006). Two members of the troponin complex, cardiac tropinin T, which binds to 
tropomyosin, and cardiac tropinin I, which regulates Ca2+-sensitive muscle contraction, are 
also present in hESC-CMs (Kehat et al., 2001; Xu, C. et al., 2002; Norstrom et al., 2006). At the 
ultrastructural level, hESC-CMs show clearly identifiable sarcomeres and intercalated discs 
(Kehat et al., 2001; Snir et al., 2003). Morphologically, single hESC-CMs show spindle, 
round, and tri- or multiangular morphologies, rather than the more defined rod shape of 
mature cells (Xu, C. et al., 2002). Sarcomeric striations are organized in separated bundles, 
reminiscent of the pattern seen in human fetal CMs, and rather than the highly organized 
parallel bundles seen in human adult CMs (Mummery, C. et al., 2003). These data suggest 
that hESC-CMs display molecular and structural properties consistent with immature 
human CMs.  
4.2 Human ESC-CMs have immature Ca2+ handling properties 
4.2.1 Mechanism of Ca2+-induced Ca2+-release and Ca2+ transient 
The contractile apparatus of CMs is dependent on the rise and decay of intracellular Ca2+, 
known as the Ca2+ transient. During an action potential (AP) of adult CMs, Ca2+ entry into 
the cytosol through sarcolemmal L-type Ca2+ channels triggers the release of Ca2+ from the 
intracellular Ca2+ stores (sarcoplasmic reticulum or SR) via the ryanodine receptors (RyR). 
This process, the so-called Ca2+-induced Ca2+-release (Bers, 2002), escalates the cytosolic Ca2+ 
([Ca2+]i) to activate the contractile apparatus for contraction. For relaxation, elevated [Ca2+]i 
gets pumped back into the SR by the sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) 
and extruded by the Na+-Ca2+ exchanger (NCX) to return to the resting [Ca2+]i level. Such a 
rise and subsequent decay of [Ca2+]i is known as Ca2+ transient. Given the central 
importance of Ca2+-induced Ca2+-release in cardiac excitation-contraction coupling, proper 
Ca2+ handling properties of hESC-CMs are crucial for their successful functional integration 
with the recipient heart after transplantation. Indeed, abnormal Ca2+ handling, as in the case 
of heart failure, can even be arrhythmogenic. 
4.2.2 Human ESC-CMs have functional SRs 
Dolnikov et al (2006) were the first to study the Ca2+-handling properties of hESC-CMs in 
detail (Dolnikov et al., 2006). They reported that Ca2+ transients recorded from spontaneously 
beating or electrically stimulated hESC-CMs respond to neither caffeine nor ryanodine; hESC-
CMs recorded as beating clusters also displayed a negative force-frequency relationship that is 
different from adult CMs. Based on these observations, the authors concluded that hESC-CMs 
are immature, do not express functional SRs, and that their contractions result from trans-
sarcolemmal Ca2+ influx (rather than Ca2+ release from the SR). Given the paucity of related 
data, our laboratory performed a comprehensive analysis to better define the Ca2+ handling 
properties of hESC-CMs by comparing Ca2+ transients from hESC-CMs and human fetal left 
ventricular (LV) CMs (16–18 weeks) (Figure 1, adopted with permission from Liu et al 2007 
Stem Cells Vol. 25, No. 12: pp.3038-3044). Upon electrical stimulation, all of hESC-CMs and 
fetal LV-CMs generated similar Ca2+ transients. However, caffeine induced Ca2+ release in 65% 
of fetal LVCMs and 38% of hESC-CMs. Ryanodine significantly reduced the electrically 
evoked Ca2+ transient amplitudes of caffeine-responsive but not -insensitive hESC-CMs and 
slowed their upstroke; thapsigargin, which inhibits SERCA, reduced the amplitude of only 
caffeine-responsive hESC-CMs and slowed the decay (Liu et al., 2007). The discrepancy 
between our findings and those of Dolnikov et al can be largely attributed to the newly 
identified caffeine-responsive population.  
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Fig. 1. Ca2+ handling properties of hESC-CMs 
A) Representative tracings caffeine-induced Ca2+ transients of hESC-CMs (HES2-, H1-CMs) 
and fetal (F) LV-CMs. B) % of caffeine-responsive and -insensitive cells. C) Expression of 
various Ca2+ handling proteins. -actin was used as the loading control. D) Immunostaining of 
RyRs. Adopted with permission from Liu et al 2007 Stem Cells Vol. 25, No. 12: pp.3038-3044.  
4.2.3 Differential expression of Ca2+ handling proteins 
While hESC-CMs express functional SRs, their Ca2+ handling properties are immature and 
are similar to those of fetal CMs. The functional immaturity of hESC-CMs may be attributed 
to the expression pattern of Ca2+ handling proteins (Figure 1C) (summarized in Table 1, 
adopted with permission from Kong et al 2010 Thromb Haemost Vol. 104, No. 1: pp.30-38).  
Compared to adult CMs, hESC-CMs express significantly lower levels of RyR, SERCA, 
phospholamban, calsequestrin and higher levels of calreticulin and NCX (Liu et al., 2007). 
The regulatory proteins junctin, triadin, and calsequestrin (CSQ) are expressed in adult LV-
CMs but are completely absent in hESC-CMs (Liu et al., 2007).  
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 hESC-CMs Fetal LVCMs Adult LVCMs 
RyR ++ ++ ++++ 
SERCA +++ +++ ++++ 
Phospholamban - ++ ++++ 
CSQ/Triadin/Junctin - + ++++ 
Calreticulin ++++ ++++ + 
NCX +++ ++++ + 
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s Basal [Ca2+]i ++ +++ ++++ 
Amplitude ++ ++ ++++ 
Decay ++ ++ ++++ 
Upstroke ++ ++ ++++ 
Table 1. Ca2+ handling properties of hESC-CMs, fetal and adult LVCMs. 
Adopted with permission from Kong et al 2010 Thromb Haemost Vol. 104, No. 1: pp.30-38. 
4.2.4 T-Tubules are absent in hESC-CMs 
Transverse (t) tubules are invaginations in the sarcolemmal membrane that concentrate 
dihydropyridine receptors and bring them spatially close to RyRs residing on the SR 
membrane located deeper in the cytoplasm (Brette and Orchard, 2003; Brette and Orchard, 
2007). By physically minimizing the diffusion distance, RyRs in CMs can participate in Ca2+-
induced Ca2+-release without a lag. The result is a synchronized, faster, and greater transient 
[Ca2+]i increase from the peripheries to the center, creating a uniform Ca2+ wavefront across 
the transverse section with simultaneous recruitment of all SR. Fast and synchronized 
activation of RyRs translates into a greater Ca2+ transient amplitude, recruitment of more 
actin–myosin cross-bridge cycling, and generation of greater contractile force. The presence 
of t-tubules is therefore crucial to the mature Ca2+ handling of CMs. Lieu et al used 
fluorescent staining (Figure 2A and C, adopted with permission from Lieu et al 2009 Stem 
Cells Dev Vol. 18, No. 10: pp.1493-1500) and atomic force microscopy (Figure 2B and D) to 
detect the presence of t-tubules and showed that the latter is absent in hESC-CMs. 
Consistent with CMs deficient of t-tubules, hESC-CMs also exhibit a U-shaped Ca2+ 
wavefront that is caused by a delayed Ca2+ increase in the central region of the cell relative 
to the peripheral region (Lieu et al., 2009) (Figure 2E). 
4.2.5 Attempts to improve Ca2+-handling properties by genetic modification 
We hypothesize that the differential expression of key CM proteins underpins the 
immaturity of hESC-CMs relative to adult CMs. We tested this idea by overexpressing CSQ 
in hESC-CMs. CSQ is the most abundant, high-capacity but low-affinity, Ca2+-binding 
protein in the SR that is anchored to the RyR. The cardiac isoform CSQ2 can store up to 20 
mM Ca2+ while buffering the free SR [Ca2+] at ~1 mM. This allows repetitive muscle 
contractions without rundown. While CSQ is robustly expressed in adult CMs, it is 
completely absent in hESC-CMs (Liu et al., 2007). We hypothesized that forced expression of 
CSQ in hESC-CMs would induce functional improvement of SR. We tested this hypothesis 
by transduction of hESC-CMs with the recombinant adenovirus Ad-CMV-CSQ-IRES-GFP 
(Ad-CSQ) and demonstrated that Ad-CSQ significantly increased the transient amplitude, 
upstroke velocity, and transient decay compared with the control and a truncated mutant 
(Liu et al., 2009) (Figure 3, adopted with permission from Liu et al 2009 Am J Physiol Cell  
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Fig. 2. T-tubule imaging of a hESC-CM and a mature ventricular CM.   
Confocal microscopic images of a hESC-CM (A) did not show intracellular fluorescent spots 
like those in an adult guinea pig ventricular CM (C) suggesting the absence of t-tubules.  
The absence of t-tubules in ESC-CMs was further confirmed by atomic force microscopy 
imaging of an adult ventricular cardiomyocyte (D) showing regularly spaced pores in the 
sarcolemma that coincide with the Z-lines, while hESC-CM (B surface showed 
comparatively smoother topology with no presence of invaginations that are indicative of t-
tubules. E) Electrically induced Ca2+ transient in hESC-CMs. Top: Time progression 
linescans of pseudo-colored transient increase in intracellular Ca2+ across the mid-plane of a 
hESC-CM showed a U-shaped wavefront.  Bottom: Quantified Ca2+ transient of linescans of 
the top panel. Adopted with permission from Lieu et al 2009 Stem Cells Dev Vol. 18, No. 10: 
pp.1493-1500. 
Physiol Vol. 297, No. 1: pp.C152-159). These results showed that immature Ca2+-handling 
properties of hESC-CMs can be rescued by genetic modification and improved our 
understanding of CM maturation. 
4.3 Human ESC-CMs demonstrate immature electrophysiological properties similar to 
‘embryonic’ CMs 
He et al (2003) were the first to study the electrophysiological properties of hESC-CMs (He 
et al., 2003). They characterized the contractions and action potentials (APs) from beating EB 
outgrowths cultured for 40 to 95 days and showed that hESC can differentiate into a 
heterogeneous mixture of CMs, with APs classified as ‘nodal-like’, ‘embryonic ventricular-
like’ and ‘embryonic atrial-like’, analogous to CM specification into pacemaker, ventricular 
and atrial CMs. The latter two classes are considered ‘embryonic’ based on their Maximum 
diastolic potential and more depolarized resting membrane potential, and “slow” type APs 
based on low dV/dtmax. Unlike adult CMs, which are normally electrically silent yet are 
excitable upon stimulation, the majority of hESC-CMs fire spontaneously, exhibiting a high 
degree of automaticity. Our laboratory examined triggered activity and found that 
‘embryonic ventricular-like’ CMs exhibit delayed after depolarization, suggesting that 
hESC-CMs can be arrhythmogenic.  
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Fig. 3. Effect of CSQ overexpression on hESC-CMs.   
A) Representative electrically-induced Ca2+ transient tracings for Ad-GFP (n=12) and Ad-
CSQ (n=29) and Ad-CSQ (truncated mutant) (n=14) transduced hESC-CMs. B) Bar graphs 
of amplitude.* P < 0.05, ** P < 0.01. Adopted with permission from Liu et al 2009 Am J 
Physiol Cell Physiol Vol. 297, No. 1: pp.C152-159. 
Subsequent studies were done to assess if hESC-CMs mature over time to acquire 
electrophysiological properties that are comparable to those of adult CMs and results are 
conflicting. Sartiani et al (2007) examined the AP of CMs over 3 months of culture and 
concluded that the molecular and functional expression of ion channels in hESC-CMs 
change over time, although they still do not reach the phenotype typical of adult VCMs 
(Sartiani et al., 2007). This is in contrast to findings by Pekkanen-Mattila et al (2010), which 
show that although one third of hESC-CMs exhibit a more mature phenotype, these changes 
are not correlated with time in culture (Pekkanen-Mattila et al., 2010). Taken together, these 
data suggest that hESC-CMs are functionally immature and present an arrhythmogenic risk. 
Therefore, facilitated in vitro maturation is important for the translation of hESC-CMs to the 
clinic and other applications (such as disease modeling, drug discovery and cardiotoxicity 
screening).  
Our group sought to define the immature proarrhythmic electrophysiological properties 
observed in hESC-CMs by examining the role of different currents in automaticity (Azene et 
al., 2005; Siu et al., 2006; Xue et al., 2007; Lieu et al., 2008; Chan, Y. C. et al., 2009). IK1 (the 
inward-rectifier K+ current encoded by Kir2.1), which stabilises a negative resting 
membrane potential, is important for suppressing automaticity and we hypothesize that its 
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absence in hESC-CMs may underlie their immature phenotype. Consistent with this, forced 
Kir2.1 expression alone sufficed to render the electrical phenotype indistinguishable from 
that of primary adult ventricular cells (Lieu DK, Fu JD and Li RA, unpublished data). These 
proof-of-concept experiments show that developmentally arrested Ca2+ and 
electrophysiological phenotypes of hESC-CMs can be rescued. We are currently developing 
a non-genetic, non-pharmacologic method to drive global maturation, by targeting the 
microenvironmental niches and other non-cell autonomous means. 
5. The use of hESC-CMs for myocardial repair and bioartificial pacemakers 
Myocardial infarction is the major worldwide cardiovascular disorder in humans and is the 
leading cause of death in many parts of the world. Immediately after a heart attack, oxygen 
starvation of myocardial tissues leads to cell death, often resulting in irreversible and 
permanent damage to the heart. Despite some improvements in short term management of 
acute myocardial infarction, long term prognosis remains poor. Sudden cardiac death due to 
ventricular arrhythmias remains a leading cause of morbidity and mortality in the 
industrialised world, claiming well over 300,000 lives annually in the United States alone. 
After myocardial infarction, the heart undergoes hypertrophy in an attempt to compensate 
for loss of CMs, and cardiac fibroblasts secrete collagen and other extracellular matrix 
proteins during scar formation, leading to impaired cardiac function. Since terminally 
differentiated CMs have very limited potential for regeneration, transplantation is the only 
treatment for end-stage heart failure. However, this is hampered by the lack of suitable 
donor organs and tissues. Cell-based therapy is thus a promising option for myocardial 
repair. A range of cell sources have been considered, including bone marrow cells, skeletal 
myoblasts and smooth muscle cells, but their non-cardiac identity has presented major 
problems. They either do not differentiate into the cardiac lineage or they do not integrate 
well into the host myocardium (Menasche et al., 2003; Smits et al., 2003; Balsam et al., 2004; 
Murry et al., 2004). As discussed in previous sections, hESC-CMs have functional and 
structural properties very similar to human embryonic/fetal CMs and is therefore a very 
promising cell source. Transplantation of hESC-CMs to mouse/rat hearts showed that the 
cells survived, formed myocardial tissue and promoted functional improvement in rat 
models of myocardial infarction (Laflamme et al., 2007; Mignone et al., 2010). More detailed 
studies into the maturation of hESC-CMs, as well as the electropysiological consequences of 
hESC-CM transplantation are required before these early successes can be translated into 
clinical therapies. 
Normal rhythms originate in the SA node (SAN), a specialized cardiac tissue consisting of 
only a few thousands pacemaker cells. Malfunction of cardiac pacemaker cells due to 
disease or aging can cause rhythm generation disorders. Current treatments include 
pharmacological intervention and/or implantation of electronic pacemakers, but they are 
associated with significant shortcomings (e.g. increased susceptibility to infection, 
haemorrhage, lung collapse and death infection, finite battery life, patient discomfort related 
to the permanent implantation of a foreign device, and lack of intrinsic responsiveness to 
neural and hormonal regulation). Therefore ‘bioartificial-pacemakers’, made up of 
transplanted cells with pacemaker properties, may be a desirable alternative. 
There are two major strategies for creating bioartificial-pacemakers. The first is to confer 
pacemaker ability on cells that are normally silent. For instance, adult atrial and ventricular 
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CMs are electrically silent unless they are stimulated by signals transmitted from the SAN. 
This is due to the absence of If, encoded by the HCN channel family, and the presence of IK1. 
Several gene-based approaches have been pursued to induce pacemaker activity in these 
normally silent cells. Our group took a protein engineering approach to define criteria 
important for pacing and created a bioengineered construct of HCN (Lesso and Li, 2003; 
Tsang et al., 2004; Tsang et al., 2004; Tse et al., 2006; Xue et al., 2007). This engineered-
construct was shown to produce pacing in vitro and in vivo (Tse et al., 2006; Xue et al., 2007). 
In a sick sinus syndrome porcine model, pacing of the heart was restored and originated 
from the site of focal transduction in the left atrium with HCN-construct injection (Tse et al., 
2006). Somatic gene transfer to create such a gene-based bioartificial pacemaker significantly 
reduces the dependence on device-supported pacing by electronic pacemaker from 85% to 
15%. Alternatively, hESCs can be differentiated into pacemaker-like derivatives for 
transplantation to recreate a cell-based bioartificial pacemaker (Kehat et al., 2004; Xue et al., 
2005). Of note, the construction of cell-based bioartificial-pacemakers requires much fewer 
cells (several thousands) than myocardial transplantation (hundreds of millions). 
Furthermore, the spherical SAN is structurally less complex than the left ventricular 
myocardium. Our group is currently exploring the possibility of using nodal progenitors. 
We are also testing non-invasive catheter-based delivery techniques for implantation as well 
as long-term safety and efficacy. 
6. Creation of engineered cardiac tissue constructs  
The ventricular myocardium is a highly complex structure consisting of aligned, connected 
CMs, stromal cells and a vascular network systematically embedded in a mesh of 
extracellular matrix. Indeed, hESC-CMs differentiated in vitro lack the sub-cellular 
organization and higher order structural 2- or 3-dimensionality seen in adult heart. To more 
closely recapitulate the in vivo environment of the heart, various groups have used different 
approaches to manipulate the surface and geometry of the culture platform, cell and matrix 
composition. For instance, Luna et al used a tunable culture platform comprised of 
biomimetic wrinkles to simulate the heart’s complex anisotropic and multiscale architecture 
and showed that the hESC-CMs cultured on these ‘microgrooved’ substrates display the 
typical tropomyosin banding pattern consistent with organized sarcomeric structure 
patterns (Luna et al., 2011) (Figure 4, adopted with permission from Luna et al 2011 Tissue 
Eng Part C Methods Vol. 17, No. 5: pp.579-588). Quantitative assessment based on nuclei 
shape and actin organization show that the hESC-CMs exhibit increased alignment on 
microgrooved substrates compared with controls. Functionally, aligned monolayers of 
hESC-CMs display anisotropic conduction properties with distinct longitudinal and 
transverse velocities, a signature characteristic of the native heart, not seen in control 
randomly organized monolayers (Lieu, Wang, Khine and Li, unpublished data). In another 
approach to mimic the structure of the heart, the Costa lab was among the first to construct 
3-D engineered cardiac tissue constructs including cardiac papillary-like muscle strips as 
well as ventricle-like “organoid” chambers that exhibit key characteristics of cardiac 
physiology by ejecting fluid and displaying force-frequency and pressure-volume 
relationships (Kim, Do Eun et al., 2006; Lee et al., 2008). These studies were originally 
performed using rat cardiac myocytes but are now being applied to hESC/iPSC-CMs. 
Further optimization of hESC/iPSC-based cardiac tissue constructs will not only provide 
powerful tools for disease modeling, drug/cardiotoxicity screening and clinical translations, 
www.intechopen.com
 Embryonic Stem Cells – Differentiation and Pluripotent Alternatives 
 
178 
but physiologic 3D environment also promises to reveal novel insights not possible with 
conventional rigid 2D culture systems.  
 
 
Fig. 4. Confocal micrographs of hESC-derived CMs alignment on wrinkles.  
Human ESC-CMs were isolated and cultured on flat substrate (A) and wrinkle substrates  
(B) for 8 days. Green indicates tropomyosin staining, blue nuclear staining DAPI.  
C) Image processing was used to detect the orientation of the DAPI-labeled nuclei. D) 
Anisotropy analysis of control (black) versus green (on wrinkles) showing that 90° is 
direction of wrinkles. The thinner lines indicate the standard deviations. Adopted with 
permission from Luna et al 2011 Tissue Eng Part C Methods Vol. 17, No. 5: pp.579-588. 
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7. Pharmacological testing using hESC-CMs 
Adverse cardiac side effects is one of the most frequent reasons that cause drugs to be 
removed from the market. For instance, Vioxx, a once widely used COX-2 inhibitor 
prescribed to patients with arthritis and other conditions causing acute and chronic pain,  
was withdrawn from the market due to unexpected cardiotoxicity. Therefore, cardiotoxicity 
screening is necessary to test the efficacy and safety of new drug treatments. Cardiotoxicity 
arises from various mechanisms, including the modulation of signaling pathways and/or 
interference with the IKr current. The hERG channel, which produces the IKr current, is 
robustly blocked by a large class of drugs. This current has a major role in cardiac 
repolarization, so it affects the length of the action potential and the QT interval (the 
duration of ventricular depolarization and subsequent repolarization). QT prolongation 
may lead to arrhythmias, e.g. torsade de pointes, with potentially lethal consequences. Since 
adult CMs do not proliferate, animal CMs, isolated hearts or non-cardiac cells, which 
express cardiac ion channels are used although their non-human origin and instability in 
culture greatly limit their usefulness. Human ESC and hiPSC may provide an unlimited cell 
source for cardiotoxicity screening. Preliminary studies have already established that hESC-
CMs/hiPSC-CMs do express the hERG mRNA (Sartiani et al., 2007; Tanaka et al., 2009), and 
display an outward ‘IKr-like’ current that is sensitive to selective blockers of IKr and 
canonical long QT-inducing inhibitors including E4031, sotalol, and cisapride (Sartiani et al., 
2007; Caspi et al., 2009). When treated with a range of cardiac and non-cardiac drugs, hESC-
CM also exhibit dose responses predictive of clinical effects (Braam et al., 2010). These 
suggest that hESC-CMs may be a suitable model for cardiotoxicity testing, although issues 
of CM purity and maturation should be considered in the design of future experiments, as 
already discussed elsewhere. It is hoped that high-throughput pharmacological systems 
involving hESC/hiPSC-CMs will soon be developed.  
8. Human ESC-CMs/hiPSC-CMs as models of cardiovascular diseases 
The use of hESC-/hiPSC-CMs as models of cardiac disorders is an exciting area of research. 
Previously, transgenic mouse models were used to study human cardiac diseases, but these 
mouse models do not always fully recapitulate the same phenotypes as those seen in 
humans. For instance, electrophysiologically, mice also have shorter action potential 
duration and higher heart rate compared to humans (Danik et al., 2002), limiting their 
usefulness as models of some disorders such as arrhythmias. Human pluripotent stem cell 
derived CMs are therefore logical suitable alternative. Reprogramming technology 
pioneered by Yamanaka and Thomson has led to the creation of disease- or patient-specific 
iPSCs. The derivation of hiPSC from patients with a range of diseases including adenosine 
deaminase deficiency-related severe combined immunodeficiency, Shwachman-Bodian-
Diamond syndrome, Gaucher disease type III, Duchenne and Becker muscular dystrophy, 
Parkinson disease, Huntington disease, juvenile-onset, type 1 diabetes mellitus, Down 
Syndrome/trisomy 21, and the carrier state of Lesch-Nyhan syndrome has been reported 
(Park et al., 2008). More recently, Ebert et al (2009) reported the generation of hiPSC line 
from a patient of spinal muscular atrophy and these cells maintained the disease genotype 
and generated motor neurons that showed selective deficits compared to those derived from 
the patient’s unaffected mother (Ebert et al., 2009). Some advances have also been made in 
the area of cardiovascular research. For instance, hiPSC models of long-QT syndrome type 1 
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and type 2 were generated (Moretti et al., 2010; Itzhaki et al., 2011). CMs differentiated from 
these hiPSC recapitulated the electrophysiological features of the disorders such as 
prolongation of AP and arrhythmogenicity and enabled the groups to study the 
pathogenesis of the diseases. Itzhaki et al (2011) also used the hiPSC-CMs to evaluate the 
potency of existing and novel pharmacological agents that may either aggravate or 
ameliorate the long-QT syndrome type 2 disease phenotype. These studies illustrate the 
potential of human iPSC technology to model the abnormal functional phenotype of 
inherited cardiac disorders and to identify potential new therapeutic agents.  
9. Conclusion 
Adult CMs lack the potential to regenerate. Human ESC and hiPSCs, with their potential for 
unlimited self-renewal and differentiation, offer an exciting means of generating human 
CMs for research and regenerative medicine. Concentrated effort by research groups 
worldwide has resulted in higher efficiency of cardiogenic differentiation and better 
characterization of hESC-/hiPSC-CMs. Experiments using animal models have 
demonstrated functional improvement after hESC-CM transplantation. However, 
substantial hurdles have to be overcome before hESC-/hiPSC-CMs can be translated into 
clinical applications. For instance, hESC-CMs are functionally immature, limiting their use 
for transplantation and as disease models. More studies are required to evaluate the long 
term effect of hESC-/hiPSC-CMs transplantation. Nonetheless, there is much reason to 
believe that hESC and hiPSC technology will bring significant benefit to cardiac research 
and treatment.  
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